| 0.3716 0.024 (6.84%) | 05-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.64 | 1-year : | 0.79 |
| Resists | First : | 0.55 | Second : | 0.68 |
| Pivot price | 0.48 |
|||
| Supports | First : | 0.34 | Second : | 0.28 |
| MAs | MA(5) : | 0.41 |
MA(20) : | 0.5 |
| MA(100) : | 0.89 |
MA(250) : | 1.3 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.6  |
D(3) : | 6.6 |
| RSI | RSI(14): 29.4 |
|||
| 52-week | High : | 2.03 | Low : | 0.34 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BDSX ] has closed above bottom band by 4.3%. Bollinger Bands are 8.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.38 - 0.38 | 0.38 - 0.39 |
| Low: | 0.35 - 0.35 | 0.35 - 0.35 |
| Close: | 0.37 - 0.37 | 0.37 - 0.38 |
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Sun, 11 May 2025
Farallon Capital Management LLC Sells 825,365 Shares of Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
Sun, 04 May 2025
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Tue, 29 Apr 2025
Biodesix (BDSX) Target Price Reduced by Canaccord Amid Market Ch - GuruFocus
Tue, 29 Apr 2025
Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025 - GlobeNewswire
Sat, 19 Apr 2025
Investors Give Biodesix, Inc. (NASDAQ:BDSX) Shares A 33% Hiding - simplywall.st
Thu, 06 Mar 2025
Analysts Have Been Trimming Their Biodesix, Inc. (NASDAQ:BDSX) Price Target After Its Latest Report - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 146 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 48.2 (%) |
| Held by Institutions | 38.7 (%) |
| Shares Short | 1,050 (K) |
| Shares Short P.Month | 1,160 (K) |
| EPS | -0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.14 |
| Profit Margin | -60.2 % |
| Operating Margin | -32.1 % |
| Return on Assets (ttm) | -21.9 % |
| Return on Equity (ttm) | -337.3 % |
| Qtrly Rev. Growth | 39.2 % |
| Gross Profit (p.s.) | 0.38 |
| Sales Per Share | 0.48 |
| EBITDA (p.s.) | -0.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -49 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -1.13 |
| PEG Ratio | 0 |
| Price to Book value | 2.65 |
| Price to Sales | 0.76 |
| Price to Cash Flow | -1.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|